Allworth Financial’s Protalix BioTherapeutics PLX Stock Holding History

Allworth Financial’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$57	Buy	+26	New	+$65	﹤0.01%	5057

Other funds holding PLX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Allworth Financial's PLX Position: Q1 2026 in Review

Allworth Financial opened a new position in Protalix BioTherapeutics (PLX) in Q1 2026: 26 shares worth $57. The stake represents ﹤0.01% of the portfolio and ranks #5057 among its holdings.

99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

Allworth Financial held 26 shares of Protalix BioTherapeutics worth $57 as of Q1 2026.
Protalix BioTherapeutics was a new Allworth Financial position in Q1 2026.
Protalix BioTherapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q1 2026, its #5057 holding.
99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Allworth Financial's 13F filing for Q1 2026, filed 15 May 2026.